Fintel reports that on June 27, 2025, BMO Capital downgraded their outlook for Verve Therapeutics (NasdaqGS:VERV) from ...

BMO Capital Markets downgraded Verve Therapeutics to Market perform, saying Eli Lilly’s agreement to buy the gene-editing specialist leaves limited room for the stock to rise before the transaction is ...

Eli Lilly has announced its intention to acquire Verve Therapeutics, a biotechnology company specializing in gene-editing ...

Jefferies analysts called the proxy filing, which is a standard disclosure after a merger agreement, “much more intriguing ...

Verve Therapeutics, a clinical-stage biotechnology company, focuses on developing gene editing medicines for cardiovascular disease treatment, making it a strategic acquisition for Eli Lilly’s ...

HealthDay News — Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront. The deal gives Lilly a potential new treatment for heart disease, The Wall ...

Verve Therapeutics, Inc. is expected to issue its next earnings report on 08/04/2025. In the previous quarter, Verve Therapeutics, Inc. reported $-0.35 (diluted) earnings per share.

Eli Lilly has confirmed plans for a $1.3 billion takeover bid for Verve Therapeutics, upgrading a collaboration between the two companies that dates back to 2023.

A common blood test can flag early Alzheimer's disease patients who are four times more likely to experience rapid brain decline, a new study says.

Verve Therapeutics has started dosing patients in a phase 1b trial of its in vivo gene-editing drug for high cholesterol, designed to permanently switch off the PCSK9 gene with a one-shot treatment.